Caricamento...

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects

Maraviroc is a C‐C chemokine receptor type‐5 antagonist approved for the treatment of HIV‐1. Previous studies show that cytochrome P450 3A5 (CYP3A5) plays a role in maraviroc metabolism. CYP3A5 is subject to a genetic polymorphism. The presence of 2 functional alleles (CYP3A5*1/*1) confers the exten...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Pharmacol
Autori principali: Vourvahis, Manoli, McFadyen, Lynn, Nepal, Sunil, Valluri, Srinivas Rao, Fang, Annie, Fate, Gwendolyn D., Wood, Linda S., Marshall, Jean‐Claude, Chan, Phylinda L. S., Nedderman, Angus, Haynes, Julian, Savage, Mark E., Clark, Andrew, Smith, Kimberly Y., Heera, Jayvant
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2018
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6586010/
https://ncbi.nlm.nih.gov/pubmed/30192390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1306
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !